OCM
HRTX icon

Orchard Capital Management’s Heron Therapeutics HRTX Stock Holding History

Orchard Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$544K Hold
680,432
– – 0.57% 31
2025
Q4 		$885K Buy
680,432
+3,142
+0.5% +$3.88K 0.77% 28
2025
Q3 		$853K Buy
677,290
+17,357
+3% +$27.5K 0.74% 29
2025
Q2 		$1.37M Sell
659,933
-771,825
-54% -$1.58M 1.51% 24
2025
Q1 		$3.15M Sell
1,431,758
-444,702
-24% -$863K 2.15% 23
2024
Q4 		$2.84M Sell
1,876,460
-103,738
-5% -$168K 1.12% 29
2024
Q3 		$3.95M Sell
1,980,198
-263,228
-12% -$629K 1.36% 30
2024
Q2 		$7.85M Sell
2,243,426
-28,457
-1% -$87.4K 2.37% 21
2024
Q1 		$6.29M Buy
2,271,883
+28,457
+1% +$71.5K 1.85% 31
2023
Q4 		$3.81M Buy
2,243,426
+100,603
+5% +$111K 1.19% 34
2023
Q3 		$2.21M Buy
2,142,823
+751,743
+54% +$1.07M 0.82% 36
2023
Q2 		$1.61M Hold
1,391,080
– – 0.54% 37
2023
Q1 		$2.1M Hold
1,391,080
– – 0.7% 36
2022
Q4 		$3.48M Hold
1,391,080
– – 1.17% 35
2022
Q3 		$5.87M Buy
1,391,080
+365,056
+36% +$1.43M 2.2% 25
2022
Q2 		$2.85M Buy
1,026,024
+59,100
+6% +$237K 0.89% 34
2022
Q1 		$5.53M Buy
966,924
+600,920
+164% +$4.4M 1.57% 30
2021
Q4 		$3.34M Buy
366,004
+7,100
+2% +$72.5K 0.98% 32
2021
Q3 		$3.84M Hold
358,904
– – 1.15% 31
2021
Q2 		$5.57M Buy
+358,904
New +$5.71M 1.61% 31

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Orchard Capital Management's HRTX Position: Q1 2026 in Review

Orchard Capital Management held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 680,432 shares worth $544K. The position accounts for 0.57% of the portfolio, ranked #31.

Orchard Capital Management first reported a position in HRTX in Q2 2021 and has held it in 20 quarters since. The position peaked at $7.85M in Q2 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Orchard Capital Management held 680,432 shares of Heron Therapeutics worth $544K as of Q1 2026.
  • Orchard Capital Management left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up 0.57% of Orchard Capital Management's portfolio in Q1 2026, its #31 holding.
  • Orchard Capital Management first reported a position in Heron Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Orchard Capital Management's Heron Therapeutics position peaked at $7.85M in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Orchard Capital Management's 13F filing for Q1 2026, filed 13 May 2026.